News

Patients treated with SAGE-217 had significantly improved depression scores and were more likely to achieve remission than those receiving placebo.

The 24-2 visual field test was comparably worse than other tests in consideration to glaucoma patients' central vision.

The FDA has approved RFPi Inc’s blood flow and perfusion imaging medical device, iCertainty.

A Norwegian-based study found that the risk of pediatric asthma increases in children of mothers who had experienced miscarriages early in pregnancy.

The fact that nearly 7 of every 10 Alzheimer diagnoses are made in women is not just associated with longer age expectancy.

A series of recently presented studies support the notion of treating hepatitis C in patients already on opioid substitution therapy.

A new method assessing the influenza A strain provides investigators a more detailed look at flu viruses.

The Second Chance app from University of Washington investigators is seeking FDA consideration in the near future.

Medical students’ perceptions of the barriers to applying for a dermatology residency vary based on race, ethnicity, and socioeconomic background.

Lower respiratory tract infections linked to influenza were responsible for an estimated 145,000 deaths worldwide in 2017.

A recent longitudinal study assessment 3 decades of patient progress in Copenhagen found no significant association between BMI and airway hyperresponsiveness.

The reported rate of outpatient visits for influenza-like illness increased to 4.1%—well above the national baseline of 2.2%, and 1.5% greater than the rate reported midway through December.

The FDA has approved EyeBOX, the first non-invasive, baseline-free tool directed at diagnosing concussions.

The FDA has expanded approval for the Embrace smartband to be used by children aged 6 years and older with epilepsy.

A prior asthma exacerbation is associated with a 2.5-fold increase in the odds of a future severe exacerbation.

The ProAir Digihaler, from Teva, will reach the US markets widescale in 2020 after receiving FDA approval.

Crizanlizumab is being developed to prevent painful and unpredictable vaso-occlusive crises in patients with sickle cell disease.

Canadian investigators identified the role of media in both promulgating and mitigating stigma of PrEP for preventing HIV transmission.

Analysis of data from phase 2 and 3 trials supports an HCV genotype 3 indication for glecaprevir/pibrentasvir, and confirms its efficacy over 8 weeks.

A lead investigator explains the findings of how active choice intervention in patient's electronic health records helps to increase vaccination rates.

Re-establishing the doctor-patient bond is critical, especially in an era of more informed patients and increasing physician burnout.

The FDA has approved 2 new dosages of the pain reliever that combines benzhydrocodone and acetaminophen.

The WEB Aneurysm Embolization System is designed to treat intracranial wide neck bifurcation aneurysms.

New research finds patients face a higher risk of pneumonia if they are taking opioids. The danger is even more pronounced for patients living with HIV.

The study implies that B-cell depletion by rituximab therapy may be therapeutically beneficial in patients with secondary progressive multiple sclerosis.

A new analysis finds racial and ethnic disparities vary significantly from state to state when it comes to sexually transmitted infection rates among men who have sex with men.

Patient and caregiver assessments should be considered alongside clinician assessments during tardive dyskinesia screening procedures, as they may differ.

It remains unclear whether clozapine treats or suppresses the symptoms of tardive dyskinesia.